Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization

The COVID-19 pandemic continues to wreak havoc as worldwide SARS-CoV-2 infection, hospitalization, and death rates climb unabated. Effective vaccines remain the most promising approach to counter SARS-CoV-2. Yet, while promising results are emerging from COVID-19 vaccine trials, the need for multipl...

Full description

Saved in:
Bibliographic Details
Published inCommunications biology Vol. 4; no. 1; pp. 597 - 9
Main Authors Chiba, Shiho, Frey, Steven J., Halfmann, Peter J., Kuroda, Makoto, Maemura, Tadashi, Yang, Jie E., Wright, Elizabeth R., Kawaoka, Yoshihiro, Kane, Ravi S.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 19.05.2021
Nature Publishing Group
Nature Portfolio
Subjects
13/1
631/250/590
692/699/255
Animals
Antibodies, Neutralizing - biosynthesis
Antibodies, Viral - biosynthesis
Biology
Biomedical and Life Sciences
Coat protein
Coronaviruses
COVID-19
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - genetics
COVID-19 Vaccines - immunology
Drug Delivery Systems
Female
Humans
Immunization
Immunization - methods
Levivirus - genetics
Levivirus - immunology
Life Sciences
Mesocricetus
Microscopy, Electron, Transmission
Models, Animal
Nanoparticles
Nanoparticles - administration & dosage
Nanoparticles - ultrastructure
Nanotechnology
Pandemics
Pandemics - prevention & control
Phages
Protein Engineering
Rodents
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus - administration & dosage
Spike Glycoprotein, Coronavirus - immunology
Vaccines
Vaccines, Combined - administration & dosage
Vaccines, Combined - genetics
Vaccines, Combined - immunology
Vaccines, Virus-Like Particle - administration & dosage
Vaccines, Virus-Like Particle - genetics
Vaccines, Virus-Like Particle - immunology
Online AccessGet full text

Cover

Abstract The COVID-19 pandemic continues to wreak havoc as worldwide SARS-CoV-2 infection, hospitalization, and death rates climb unabated. Effective vaccines remain the most promising approach to counter SARS-CoV-2. Yet, while promising results are emerging from COVID-19 vaccine trials, the need for multiple doses and the challenges associated with the widespread distribution and administration of vaccines remain concerns. Here, we engineered the coat protein of the MS2 bacteriophage and generated nanoparticles displaying multiple copies of the SARS-CoV-2 spike (S) protein. The use of these nanoparticles as vaccines generated high neutralizing antibody titers and protected Syrian hamsters from a challenge with SARS-CoV-2 after a single immunization with no infectious virus detected in the lungs. This nanoparticle-based vaccine platform thus provides protection after a single immunization and may be broadly applicable for protecting against SARS-CoV-2 and future pathogens with pandemic potential. Chiba et al. describe the use of MS2 bacteriophage coat proteins to develop nanocarriers that display the SARS-CoV-2 spike proteins multivalently for vaccine applications. The vaccine elicited high neutralizing antibody titers and protected Syrian hamsters from virus infection after a single immunization.
AbstractList The COVID-19 pandemic continues to wreak havoc as worldwide SARS-CoV-2 infection, hospitalization, and death rates climb unabated. Effective vaccines remain the most promising approach to counter SARS-CoV-2. Yet, while promising results are emerging from COVID-19 vaccine trials, the need for multiple doses and the challenges associated with the widespread distribution and administration of vaccines remain concerns. Here, we engineered the coat protein of the MS2 bacteriophage and generated nanoparticles displaying multiple copies of the SARS-CoV-2 spike (S) protein. The use of these nanoparticles as vaccines generated high neutralizing antibody titers and protected Syrian hamsters from a challenge with SARS-CoV-2 after a single immunization with no infectious virus detected in the lungs. This nanoparticle-based vaccine platform thus provides protection after a single immunization and may be broadly applicable for protecting against SARS-CoV-2 and future pathogens with pandemic potential.
Chiba et al. describe the use of MS2 bacteriophage coat proteins to develop nanocarriers that display the SARS-CoV-2 spike proteins multivalently for vaccine applications. The vaccine elicited high neutralizing antibody titers and protected Syrian hamsters from virus infection after a single immunization.
The COVID-19 pandemic continues to wreak havoc as worldwide SARS-CoV-2 infection, hospitalization, and death rates climb unabated. Effective vaccines remain the most promising approach to counter SARS-CoV-2. Yet, while promising results are emerging from COVID-19 vaccine trials, the need for multiple doses and the challenges associated with the widespread distribution and administration of vaccines remain concerns. Here, we engineered the coat protein of the MS2 bacteriophage and generated nanoparticles displaying multiple copies of the SARS-CoV-2 spike (S) protein. The use of these nanoparticles as vaccines generated high neutralizing antibody titers and protected Syrian hamsters from a challenge with SARS-CoV-2 after a single immunization with no infectious virus detected in the lungs. This nanoparticle-based vaccine platform thus provides protection after a single immunization and may be broadly applicable for protecting against SARS-CoV-2 and future pathogens with pandemic potential. Chiba et al. describe the use of MS2 bacteriophage coat proteins to develop nanocarriers that display the SARS-CoV-2 spike proteins multivalently for vaccine applications. The vaccine elicited high neutralizing antibody titers and protected Syrian hamsters from virus infection after a single immunization.
The COVID-19 pandemic continues to wreak havoc as worldwide SARS-CoV-2 infection, hospitalization, and death rates climb unabated. Effective vaccines remain the most promising approach to counter SARS-CoV-2. Yet, while promising results are emerging from COVID-19 vaccine trials, the need for multiple doses and the challenges associated with the widespread distribution and administration of vaccines remain concerns. Here, we engineered the coat protein of the MS2 bacteriophage and generated nanoparticles displaying multiple copies of the SARS-CoV-2 spike (S) protein. The use of these nanoparticles as vaccines generated high neutralizing antibody titers and protected Syrian hamsters from a challenge with SARS-CoV-2 after a single immunization with no infectious virus detected in the lungs. This nanoparticle-based vaccine platform thus provides protection after a single immunization and may be broadly applicable for protecting against SARS-CoV-2 and future pathogens with pandemic potential.The COVID-19 pandemic continues to wreak havoc as worldwide SARS-CoV-2 infection, hospitalization, and death rates climb unabated. Effective vaccines remain the most promising approach to counter SARS-CoV-2. Yet, while promising results are emerging from COVID-19 vaccine trials, the need for multiple doses and the challenges associated with the widespread distribution and administration of vaccines remain concerns. Here, we engineered the coat protein of the MS2 bacteriophage and generated nanoparticles displaying multiple copies of the SARS-CoV-2 spike (S) protein. The use of these nanoparticles as vaccines generated high neutralizing antibody titers and protected Syrian hamsters from a challenge with SARS-CoV-2 after a single immunization with no infectious virus detected in the lungs. This nanoparticle-based vaccine platform thus provides protection after a single immunization and may be broadly applicable for protecting against SARS-CoV-2 and future pathogens with pandemic potential.
The COVID-19 pandemic continues to wreak havoc as worldwide SARS-CoV-2 infection, hospitalization, and death rates climb unabated. Effective vaccines remain the most promising approach to counter SARS-CoV-2. Yet, while promising results are emerging from COVID-19 vaccine trials, the need for multiple doses and the challenges associated with the widespread distribution and administration of vaccines remain concerns. Here, we engineered the coat protein of the MS2 bacteriophage and generated nanoparticles displaying multiple copies of the SARS-CoV-2 spike (S) protein. The use of these nanoparticles as vaccines generated high neutralizing antibody titers and protected Syrian hamsters from a challenge with SARS-CoV-2 after a single immunization with no infectious virus detected in the lungs. This nanoparticle-based vaccine platform thus provides protection after a single immunization and may be broadly applicable for protecting against SARS-CoV-2 and future pathogens with pandemic potential.Chiba et al. describe the use of MS2 bacteriophage coat proteins to develop nanocarriers that display the SARS-CoV-2 spike proteins multivalently for vaccine applications. The vaccine elicited high neutralizing antibody titers and protected Syrian hamsters from virus infection after a single immunization.
ArticleNumber 597
Author Wright, Elizabeth R.
Yang, Jie E.
Kuroda, Makoto
Kawaoka, Yoshihiro
Kane, Ravi S.
Frey, Steven J.
Halfmann, Peter J.
Maemura, Tadashi
Chiba, Shiho
Author_xml – sequence: 1
  givenname: Shiho
  orcidid: 0000-0003-0415-6013
  surname: Chiba
  fullname: Chiba, Shiho
  organization: Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin
– sequence: 2
  givenname: Steven J.
  orcidid: 0000-0003-1863-694X
  surname: Frey
  fullname: Frey, Steven J.
  organization: School of Chemical & Biomolecular Engineering, Georgia Institute of Technology
– sequence: 3
  givenname: Peter J.
  surname: Halfmann
  fullname: Halfmann, Peter J.
  organization: Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin
– sequence: 4
  givenname: Makoto
  surname: Kuroda
  fullname: Kuroda, Makoto
  organization: Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin
– sequence: 5
  givenname: Tadashi
  surname: Maemura
  fullname: Maemura, Tadashi
  organization: Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin
– sequence: 6
  givenname: Jie E.
  orcidid: 0000-0002-2438-8156
  surname: Yang
  fullname: Yang, Jie E.
  organization: Department of Biochemistry, University of Wisconsin, Cryo-EM Research Center, Department of Biochemistry, University of Wisconsin
– sequence: 7
  givenname: Elizabeth R.
  orcidid: 0000-0003-0712-9475
  surname: Wright
  fullname: Wright, Elizabeth R.
  organization: Department of Biochemistry, University of Wisconsin, Cryo-EM Research Center, Department of Biochemistry, University of Wisconsin
– sequence: 8
  givenname: Yoshihiro
  orcidid: 0000-0001-5061-8296
  surname: Kawaoka
  fullname: Kawaoka, Yoshihiro
  email: yoshihiro.kawaoka@wisc.edu
  organization: Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo
– sequence: 9
  givenname: Ravi S.
  orcidid: 0000-0003-3084-4098
  surname: Kane
  fullname: Kane, Ravi S.
  email: ravi.kane@chbe.gatech.edu
  organization: School of Chemical & Biomolecular Engineering, Georgia Institute of Technology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34011948$$D View this record in MEDLINE/PubMed
BookMark eNp9Ustu1DAUjVARLaU_wAJFYsMmcG1nPPEGqRrxqFSERIGtde3cpB4l9mAnI8HX484Mpe2iC8uPe87xuY_nxZEPnoriJYO3DETzLtUcQFTA2c3iTdU8KU64UKoSsuZHd87HxVlKawBgSikp6mfFsaiBMVU3J0X_ZR4mt8WB_FR69GGDcXJ2oMpgorbcorXOUyo3MUxkp_IaxzRRTCX26Hyayqvzb1fVKvyseIldjpRYJuf7gUo3jrN3f3Bywb8onnY4JDo77KfFj48fvq8-V5dfP12szi8rK0FOFSpCIEO0wGVjGPDOqFoaZZhatLYGrAnk0sBS5Ztp1UISICne4UK2nIM4LS72um3Atd5EN2L8rQM6vXsIsdeHBDVZa4GElALaWsDSsFa2yLgBQNOBylrv91qb2YzU2lyiiMM90fsR7651H7a6YaKuFc8Cbw4CMfyaKU16dMnSMKCnMCfNF1wpwYRcZujrB9B1mKPPpdqhINupWUa9uuvo1sq_fmYA3wNsDClF6m4hDPTN3Oj93Og8M3o3N_qG1DwgWTftupazcsPjVLGnpvyP7yn-t_0I6y_csNgC
CitedBy_id crossref_primary_10_1002_adma_202107781
crossref_primary_10_1021_acs_bioconjchem_2c00335
crossref_primary_10_1038_s41467_023_36101_2
crossref_primary_10_1038_s41467_025_55824_y
crossref_primary_10_1038_s41541_022_00481_1
crossref_primary_10_1002_bip_23563
crossref_primary_10_3390_vaccines11040833
crossref_primary_10_1021_acsmacrolett_3c00550
crossref_primary_10_1128_mbio_03368_23
crossref_primary_10_3389_fimmu_2023_1204834
crossref_primary_10_3390_vaccines9101082
crossref_primary_10_4155_tde_2021_0075
crossref_primary_10_1038_s41467_024_45495_6
crossref_primary_10_3390_v16060936
crossref_primary_10_1021_acsabm_2c00123
crossref_primary_10_1021_acsinfecdis_2c00362
crossref_primary_10_2217_nnm_2023_0362
crossref_primary_10_1126_scitranslmed_adl1722
crossref_primary_10_3390_ijms222413445
crossref_primary_10_3389_fimmu_2024_1392898
crossref_primary_10_1146_annurev_virology_111821_111145
crossref_primary_10_1038_s41467_022_32496_6
crossref_primary_10_3390_v14051060
crossref_primary_10_1016_j_vacune_2023_02_007
crossref_primary_10_1089_mdr_2021_0281
crossref_primary_10_3390_ijms25073736
crossref_primary_10_1002_adhm_202202729
crossref_primary_10_1038_s41386_022_01311_7
crossref_primary_10_1016_j_ijbiomac_2023_123979
crossref_primary_10_1002_VIW_20200027
crossref_primary_10_1016_j_nantod_2023_101971
crossref_primary_10_3390_vaccines11091506
crossref_primary_10_1016_j_ebiom_2022_104341
crossref_primary_10_1016_j_vacun_2022_06_002
Cites_doi 10.1038/s41586-020-2180-5
10.1126/science.abb2507
10.1073/pnas.2002589117
10.1038/s41541-021-00321-8
10.1038/s41586-020-3035-9
10.1038/s41586-020-2381-y
10.1038/s41586-020-2622-0
10.1038/s41591-020-1070-6
10.1038/s41565-020-0737-y
10.1016/j.jsb.2005.07.007
10.1038/nri2868
10.1039/c9nr05145g
10.1016/j.coviro.2016.03.001
10.1016/j.jmb.2013.09.016
10.1038/s41586-020-2798-3
10.1016/j.jmb.2008.04.049
10.1002/wnan.119
10.1038/371623a0
10.1038/nprot.2008.20
10.1038/s41598-020-74949-2
10.1038/s41586-020-2380-z
10.1038/s41467-020-18319-6
10.1073/pnas.2009799117
10.1038/s41586-020-2342-5
10.1146/annurev.immunol.15.1.235
10.1371/journal.pmed.0030237
10.1038/nmeth.4193
10.1016/j.jsb.2015.04.016
10.1126/science.abd0826
10.1016/j.jsb.2021.107709
10.1016/j.cell.2020.02.058
10.3791/56482
10.3791/3227
10.1128/JCM.02107-20
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
88I
8FE
8FH
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
GNUQQ
HCIFZ
LK8
M2P
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s42003-021-02128-8
DatabaseName Open Access Journals from Springer Nature
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Open Access Journals (DOAJ)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Coronavirus Research Database
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE


MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2399-3642
EndPage 9
ExternalDocumentID oai_doaj_org_article_eccc0e36630d4307b1d6da12b00abf09
PMC8134492
34011948
10_1038_s42003_021_02128_8
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: CRIP, HHSN272201400008C
  funderid: https://doi.org/10.13039/100000060
– fundername: Garry Betty/ V Foundation Chair Fund Seed funding from the School of Chemical & Biomolecular Engineering at the Georgia Institute of Technology. Department of Biochemistry, University of Wisconsin, Madison. Cryo-EM Research Center in the Department of Biochemistry, University of Wisconsin, Madison. Collaborative Influenza Vaccine Innovation Centers (CIVIC, contract 75N93019C00051) Research Program on Emerging and Re-emerging Infectious Disease grant (JP19fk0108113) from the Japan Agency for Medical Research and Development (AMED).
– fundername: NIAID NIH HHS
  grantid: HHSN272201400008C
– fundername: NIAID NIH HHS
  grantid: 75N93019C00051
– fundername: NIGMS NIH HHS
  grantid: U24 GM139168
– fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: CRIP, HHSN272201400008C
– fundername: ;
– fundername: ;
  grantid: CRIP, HHSN272201400008C
GroupedDBID 0R~
53G
88I
AAJSJ
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
AFKRA
AJTQC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
C6C
CCPQU
DWQXO
EBLON
EBS
GNUQQ
GROUPED_DOAJ
HCIFZ
HYE
M2P
M7P
M~E
NAO
O9-
OK1
PGMZT
PIMPY
RNT
RPM
SNYQT
AASML
AAYXX
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PQGLB
3V.
7XB
8FE
8FH
8FK
AARCD
COVID
LK8
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c606t-a9ea0ebee5a78b102fb946b9b195dc40a4e067b079dc4bd956e0ae92fa56d2203
IEDL.DBID BENPR
ISSN 2399-3642
IngestDate Wed Aug 27 01:31:52 EDT 2025
Thu Aug 21 14:04:08 EDT 2025
Tue Aug 05 08:41:26 EDT 2025
Wed Aug 13 08:43:21 EDT 2025
Wed Jul 23 01:45:57 EDT 2025
Tue Jul 01 03:01:32 EDT 2025
Thu Apr 24 23:05:47 EDT 2025
Fri Feb 21 02:40:09 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-a9ea0ebee5a78b102fb946b9b195dc40a4e067b079dc4bd956e0ae92fa56d2203
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-0415-6013
0000-0003-0712-9475
0000-0001-5061-8296
0000-0002-2438-8156
0000-0003-3084-4098
0000-0003-1863-694X
OpenAccessLink https://www.proquest.com/docview/2529009341?pq-origsite=%requestingapplication%
PMID 34011948
PQID 2529009341
PQPubID 4669726
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_eccc0e36630d4307b1d6da12b00abf09
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8134492
proquest_miscellaneous_2529931367
proquest_journals_2529009341
pubmed_primary_34011948
crossref_primary_10_1038_s42003_021_02128_8
crossref_citationtrail_10_1038_s42003_021_02128_8
springer_journals_10_1038_s42003_021_02128_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-05-19
PublicationDateYYYYMMDD 2021-05-19
PublicationDate_xml – month: 05
  year: 2021
  text: 2021-05-19
  day: 19
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Communications biology
PublicationTitleAbbrev Commun Biol
PublicationTitleAlternate Commun Biol
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Galaz-Montoya, Flanagan, Schmid, Ludtke (CR33) 2015; 190
Mastronarde (CR31) 2005; 152
Shin (CR5) 2020; 15
Krammer (CR1) 2020; 586
Ju (CR15) 2020; 584
Imai (CR19) 2020; 117
Tostanoski (CR21) 2020; 26
Peabody (CR12) 2008; 380
Plummer, Manchester (CR8) 2011; 3
Shi (CR16) 2020; 584
ter Meulen (CR17) 2006; 3
Jia (CR24) 2021; 6
Matsuyama (CR34) 2020; 117
CR30
Wrapp (CR13) 2020; 367
Zhang (CR10) 2020; 10
Fairhead, Krndija, Lowe, Howarth (CR26) 2014; 426
Bachmann, Zinkernagel (CR9) 1997; 15
Arsiwala (CR23) 2019; 11
Zheng (CR32) 2017; 14
Bachmann, Jennings (CR6) 2010; 10
Sia (CR20) 2020; 583
CR4
CR3
Lan (CR14) 2020; 581
CR29
Valegard, Murray, Stockley, Stonehouse, Liljas (CR11) 1994; 371
CR28
Hsieh (CR18) 2020; 369
Corbett (CR22) 2020; 586
Sanchez-Felipe (CR25) 2021; 590
Frietze, Peabody, Chackerian (CR7) 2016; 18
Yang (CR2) 2020; 11
Howarth, Ting (CR27) 2008; 3
SQ Zheng (2128_CR32) 2017; 14
CL Hsieh (2128_CR18) 2020; 369
MF Bachmann (2128_CR9) 1997; 15
DS Peabody (2128_CR12) 2008; 380
MF Bachmann (2128_CR6) 2010; 10
B Zhang (2128_CR10) 2020; 10
B Ju (2128_CR15) 2020; 584
A Arsiwala (2128_CR23) 2019; 11
M Fairhead (2128_CR26) 2014; 426
S Matsuyama (2128_CR34) 2020; 117
JG Galaz-Montoya (2128_CR33) 2015; 190
J Yang (2128_CR2) 2020; 11
D Wrapp (2128_CR13) 2020; 367
2128_CR30
J Lan (2128_CR14) 2020; 581
R Shi (2128_CR16) 2020; 584
2128_CR29
MD Shin (2128_CR5) 2020; 15
Q Jia (2128_CR24) 2021; 6
F Krammer (2128_CR1) 2020; 586
M Imai (2128_CR19) 2020; 117
K Valegard (2128_CR11) 1994; 371
EM Plummer (2128_CR8) 2011; 3
2128_CR4
DN Mastronarde (2128_CR31) 2005; 152
2128_CR3
J ter Meulen (2128_CR17) 2006; 3
SF Sia (2128_CR20) 2020; 583
2128_CR28
KM Frietze (2128_CR7) 2016; 18
KS Corbett (2128_CR22) 2020; 586
LH Tostanoski (2128_CR21) 2020; 26
L Sanchez-Felipe (2128_CR25) 2021; 590
M Howarth (2128_CR27) 2008; 3
References_xml – volume: 581
  start-page: 215
  year: 2020
  end-page: 220
  ident: CR14
  article-title: Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
  publication-title: Nature
  doi: 10.1038/s41586-020-2180-5
– volume: 367
  start-page: 1260
  year: 2020
  end-page: 1263
  ident: CR13
  article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
  publication-title: Science
  doi: 10.1126/science.abb2507
– volume: 117
  start-page: 7001
  year: 2020
  end-page: 7003
  ident: CR34
  article-title: Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2002589117
– volume: 6
  year: 2021
  ident: CR24
  article-title: Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-021-00321-8
– volume: 590
  start-page: 320
  year: 2021
  end-page: 325
  ident: CR25
  article-title: A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
  publication-title: Nature
  doi: 10.1038/s41586-020-3035-9
– ident: CR4
– volume: 584
  start-page: 120
  year: 2020
  end-page: 124
  ident: CR16
  article-title: A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
  publication-title: Nature
  doi: 10.1038/s41586-020-2381-y
– ident: CR30
– volume: 586
  start-page: 567
  year: 2020
  end-page: 571
  ident: CR22
  article-title: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
  publication-title: Nature
  doi: 10.1038/s41586-020-2622-0
– volume: 26
  start-page: 1694
  year: 2020
  end-page: 1700
  ident: CR21
  article-title: Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
  publication-title: Nat. Med
  doi: 10.1038/s41591-020-1070-6
– volume: 15
  start-page: 646
  year: 2020
  end-page: 655
  ident: CR5
  article-title: COVID-19 vaccine development and a potential nanomaterial path forward
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/s41565-020-0737-y
– ident: CR29
– volume: 152
  start-page: 36
  year: 2005
  end-page: 51
  ident: CR31
  article-title: Automated electron microscope tomography using robust prediction of specimen movements
  publication-title: J. Struct. Biol.
  doi: 10.1016/j.jsb.2005.07.007
– volume: 10
  start-page: 787
  year: 2010
  end-page: 796
  ident: CR6
  article-title: Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri2868
– volume: 11
  start-page: 15307
  year: 2019
  end-page: 15311
  ident: CR23
  article-title: Nanopatterning protein antigens to refocus the immune response
  publication-title: Nanoscale
  doi: 10.1039/c9nr05145g
– volume: 18
  start-page: 44
  year: 2016
  end-page: 49
  ident: CR7
  article-title: Engineering virus-like particles as vaccine platforms
  publication-title: Curr. Opin. Virol.
  doi: 10.1016/j.coviro.2016.03.001
– volume: 426
  start-page: 199
  year: 2014
  end-page: 214
  ident: CR26
  article-title: Plug-and-play pairing via defined divalent streptavidins
  publication-title: J. Mol. Biol.
  doi: 10.1016/j.jmb.2013.09.016
– volume: 586
  start-page: 516
  year: 2020
  end-page: 527
  ident: CR1
  article-title: SARS-CoV-2 vaccines in development
  publication-title: Nature
  doi: 10.1038/s41586-020-2798-3
– ident: CR3
– volume: 380
  start-page: 252
  year: 2008
  end-page: 263
  ident: CR12
  article-title: Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2
  publication-title: J. Mol. Biol.
  doi: 10.1016/j.jmb.2008.04.049
– volume: 3
  start-page: 174
  year: 2011
  end-page: 196
  ident: CR8
  article-title: Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design
  publication-title: Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol
  doi: 10.1002/wnan.119
– volume: 371
  start-page: 623
  year: 1994
  end-page: 626
  ident: CR11
  article-title: Crystal structure of an RNA bacteriophage coat protein-operator complex
  publication-title: Nature
  doi: 10.1038/371623a0
– volume: 3
  start-page: 534
  year: 2008
  end-page: 545
  ident: CR27
  article-title: Imaging proteins in live mammalian cells with biotin ligase and monovalent streptavidin
  publication-title: Nat. Protoc.
  doi: 10.1038/nprot.2008.20
– volume: 10
  year: 2020
  ident: CR10
  article-title: A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-74949-2
– volume: 584
  start-page: 115
  year: 2020
  end-page: 119
  ident: CR15
  article-title: Human neutralizing antibodies elicited by SARS-CoV-2 infection
  publication-title: Nature
  doi: 10.1038/s41586-020-2380-z
– volume: 11
  year: 2020
  ident: CR2
  article-title: Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18319-6
– volume: 117
  start-page: 16587
  year: 2020
  end-page: 16595
  ident: CR19
  article-title: Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2009799117
– volume: 583
  start-page: 834
  year: 2020
  end-page: 838
  ident: CR20
  article-title: Pathogenesis and transmission of SARS-CoV-2 in golden hamsters
  publication-title: Nature
  doi: 10.1038/s41586-020-2342-5
– volume: 15
  start-page: 235
  year: 1997
  end-page: 270
  ident: CR9
  article-title: Neutralizing antiviral B cell responses
  publication-title: Annu Rev. Immunol.
  doi: 10.1146/annurev.immunol.15.1.235
– volume: 3
  start-page: e237
  year: 2006
  ident: CR17
  article-title: Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0030237
– ident: CR28
– volume: 14
  start-page: 331
  year: 2017
  end-page: 332
  ident: CR32
  article-title: MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.4193
– volume: 190
  start-page: 279
  year: 2015
  end-page: 290
  ident: CR33
  article-title: Single particle tomography in EMAN2
  publication-title: J. Struct. Biol.
  doi: 10.1016/j.jsb.2015.04.016
– volume: 369
  start-page: 1501
  year: 2020
  end-page: 1505
  ident: CR18
  article-title: Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
  publication-title: Science
  doi: 10.1126/science.abd0826
– volume: 369
  start-page: 1501
  year: 2020
  ident: 2128_CR18
  publication-title: Science
  doi: 10.1126/science.abd0826
– volume: 15
  start-page: 235
  year: 1997
  ident: 2128_CR9
  publication-title: Annu Rev. Immunol.
  doi: 10.1146/annurev.immunol.15.1.235
– ident: 2128_CR30
  doi: 10.1016/j.jsb.2021.107709
– volume: 3
  start-page: 174
  year: 2011
  ident: 2128_CR8
  publication-title: Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol
  doi: 10.1002/wnan.119
– ident: 2128_CR4
  doi: 10.1016/j.cell.2020.02.058
– volume: 14
  start-page: 331
  year: 2017
  ident: 2128_CR32
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.4193
– ident: 2128_CR29
  doi: 10.3791/56482
– ident: 2128_CR28
  doi: 10.3791/3227
– volume: 581
  start-page: 215
  year: 2020
  ident: 2128_CR14
  publication-title: Nature
  doi: 10.1038/s41586-020-2180-5
– volume: 3
  start-page: 534
  year: 2008
  ident: 2128_CR27
  publication-title: Nat. Protoc.
  doi: 10.1038/nprot.2008.20
– volume: 3
  start-page: e237
  year: 2006
  ident: 2128_CR17
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0030237
– volume: 117
  start-page: 16587
  year: 2020
  ident: 2128_CR19
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2009799117
– volume: 10
  year: 2020
  ident: 2128_CR10
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-74949-2
– volume: 152
  start-page: 36
  year: 2005
  ident: 2128_CR31
  publication-title: J. Struct. Biol.
  doi: 10.1016/j.jsb.2005.07.007
– volume: 583
  start-page: 834
  year: 2020
  ident: 2128_CR20
  publication-title: Nature
  doi: 10.1038/s41586-020-2342-5
– ident: 2128_CR3
  doi: 10.1128/JCM.02107-20
– volume: 367
  start-page: 1260
  year: 2020
  ident: 2128_CR13
  publication-title: Science
  doi: 10.1126/science.abb2507
– volume: 15
  start-page: 646
  year: 2020
  ident: 2128_CR5
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/s41565-020-0737-y
– volume: 10
  start-page: 787
  year: 2010
  ident: 2128_CR6
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri2868
– volume: 371
  start-page: 623
  year: 1994
  ident: 2128_CR11
  publication-title: Nature
  doi: 10.1038/371623a0
– volume: 584
  start-page: 120
  year: 2020
  ident: 2128_CR16
  publication-title: Nature
  doi: 10.1038/s41586-020-2381-y
– volume: 117
  start-page: 7001
  year: 2020
  ident: 2128_CR34
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2002589117
– volume: 190
  start-page: 279
  year: 2015
  ident: 2128_CR33
  publication-title: J. Struct. Biol.
  doi: 10.1016/j.jsb.2015.04.016
– volume: 11
  year: 2020
  ident: 2128_CR2
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18319-6
– volume: 6
  year: 2021
  ident: 2128_CR24
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-021-00321-8
– volume: 584
  start-page: 115
  year: 2020
  ident: 2128_CR15
  publication-title: Nature
  doi: 10.1038/s41586-020-2380-z
– volume: 590
  start-page: 320
  year: 2021
  ident: 2128_CR25
  publication-title: Nature
  doi: 10.1038/s41586-020-3035-9
– volume: 426
  start-page: 199
  year: 2014
  ident: 2128_CR26
  publication-title: J. Mol. Biol.
  doi: 10.1016/j.jmb.2013.09.016
– volume: 18
  start-page: 44
  year: 2016
  ident: 2128_CR7
  publication-title: Curr. Opin. Virol.
  doi: 10.1016/j.coviro.2016.03.001
– volume: 586
  start-page: 516
  year: 2020
  ident: 2128_CR1
  publication-title: Nature
  doi: 10.1038/s41586-020-2798-3
– volume: 26
  start-page: 1694
  year: 2020
  ident: 2128_CR21
  publication-title: Nat. Med
  doi: 10.1038/s41591-020-1070-6
– volume: 380
  start-page: 252
  year: 2008
  ident: 2128_CR12
  publication-title: J. Mol. Biol.
  doi: 10.1016/j.jmb.2008.04.049
– volume: 586
  start-page: 567
  year: 2020
  ident: 2128_CR22
  publication-title: Nature
  doi: 10.1038/s41586-020-2622-0
– volume: 11
  start-page: 15307
  year: 2019
  ident: 2128_CR23
  publication-title: Nanoscale
  doi: 10.1039/c9nr05145g
SSID ssj0001999634
Score 2.3470798
Snippet The COVID-19 pandemic continues to wreak havoc as worldwide SARS-CoV-2 infection, hospitalization, and death rates climb unabated. Effective vaccines remain...
Chiba et al. describe the use of MS2 bacteriophage coat proteins to develop nanocarriers that display the SARS-CoV-2 spike proteins multivalently for vaccine...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 597
SubjectTerms 13/1
631/250/590
692/699/255
Animals
Antibodies, Neutralizing - biosynthesis
Antibodies, Viral - biosynthesis
Biology
Biomedical and Life Sciences
Coat protein
Coronaviruses
COVID-19
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - genetics
COVID-19 Vaccines - immunology
Drug Delivery Systems
Female
Humans
Immunization
Immunization - methods
Levivirus - genetics
Levivirus - immunology
Life Sciences
Mesocricetus
Microscopy, Electron, Transmission
Models, Animal
Nanoparticles
Nanoparticles - administration & dosage
Nanoparticles - ultrastructure
Nanotechnology
Pandemics
Pandemics - prevention & control
Phages
Protein Engineering
Rodents
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus - administration & dosage
Spike Glycoprotein, Coronavirus - immunology
Vaccines
Vaccines, Combined - administration & dosage
Vaccines, Combined - genetics
Vaccines, Combined - immunology
Vaccines, Virus-Like Particle - administration & dosage
Vaccines, Virus-Like Particle - genetics
Vaccines, Virus-Like Particle - immunology
SummonAdditionalLinks – databaseName: Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuCMorpUVG4gZW_UpiH0tFVSHBgVLUmzV-pF2pZFF3i8S_Z2xnly7PC8fEk2Q0M87M2J5vCHmBv7ho0tAznoJlOiTNQAXBUm9t8kbGVLpEvHvfHZ_qt2ft2Y1WX_lMWIUHroLbx08EnhQ6Rh41GqQXsYsgJJoL-KGW7qHPu5FMldWVHMcrPVXJcGX2F7ocw8onEjKquWFmwxMVwP7fRZm_Hpb8ace0OKKje-TuFEHSg8r5fXIrjdvkdu0p-e0BOS8ltWg_-CI6wohJcaVk2WFF-hVC3ktf0AmhgV7A5wyWsKBwDjMMFunJwYcTdjj_xCQtHcQp0LygcJnorBST1MLNh-T06M3Hw2M2dVNgAZOUJQObgKPKUgu98RhXDN7qzlsvbBuD5qATei7Pe4tXPmLelDgkKwdouyglV4_I1jgf0xNCkQ64DD1IiFoMymMU1XW6Cz0PIQ28IWIlWRcmqPHc8eLSlS1vZVzVhkNNuKINZxrycv3Mlwq08Vfq11lha8oMkl1uoOm4SazuX6bTkN2Vut00cxdOttLmZR4tGvJ8PYxzLm-kwJjm15XGqgx215DH1TrWnCidUfQ0cthv2M0Gq5sj4-yi4HobobS2siGvVhb2g60_i2Lnf4jiKbkjy9RombC7ZGt5dZ32MNpa-mdlYn0HzYEmsA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3daxQxEB9qi-CL-O1qlQi-aTCbZD_yeBZLOdAHz0rfwuRjrwd1T3pXwf_eSXbvymkVfNzdyTJkJjOTZOY3AK_JxIU2dg0X0RuufdQclS95bIyJrpUh5i4RHz_VJ6d6elad7YHc1MLkpP0MaZnN9CY77N1K5yyqlFCQQMlb3t6CgwTVTrp9MJlMZ9Prk5UUwys9VsgI1d4weMcLZbD-myLMPxMlf7stzU7o-B7cHaNHNhn4vQ97sX8At4d-kj8fwjyX05Lu0I9Yjz1tiAdKnpxVYD_Qp3v0FRvRGdg5fktACSuGc1xQoMhmk88zfrT8yiXL3cMZsnSYcBHZIheSDEWbj-D0-MOXoxM-dlLgnjYoa44moiBxxQqb1lFM0Tmja2dcaargtUAdyWs50Rh6coH2TFFgNLLDqg5SCvUY9vtlH58CIzoU0jcoMeiyU44iqLrWtW-E97ETBZSbmbV-hBlP3S4ubL7uVq0dpGFJEjZLw7YFvNmO-T6AbPyT-n0S2JYyAWTnF8vLuR2n1ZJmehEVxVMiaLJjrgx1wFKSlUHXCVPA4Ubcdly1KysradIRjy4LeLX9TOstXaJgH5dXA41RCeiugCeDdmw5UToh6GnisNnRmx1Wd7_0i_OM6d2WSmsjC3i70bBrtv4-Fc_-j_w53JF5EVS8NIewv768ii8oplq7l-Mi-gWibRyd
  priority: 102
  providerName: Springer Nature
Title Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization
URI https://link.springer.com/article/10.1038/s42003-021-02128-8
https://www.ncbi.nlm.nih.gov/pubmed/34011948
https://www.proquest.com/docview/2529009341
https://www.proquest.com/docview/2529931367
https://pubmed.ncbi.nlm.nih.gov/PMC8134492
https://doaj.org/article/eccc0e36630d4307b1d6da12b00abf09
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdrwmAvY9_11gUN9raJypJsS08jDS0lsDKadfTN6MtpoLO7Jh3sv99JVhKyjz7aPhtZd7o73el-h9B7UHFO-qYi1FtFhPWCaG5z4iulvJHM-dgl4vNZeXohppfFZQq4LdOxyrVOjIradTbEyA9ZwVTYfov8080PErpGhexqaqGxh4aggqUcoOHR8dmX822UJfjzXKRqGcrl4VLE41jhZEJAN5dE7likCNz_L2_z70OTf2ROo0E6eYIeJ08Sj3vWP0UPfPsMPex7S_56juaxtBbkCD6EW93C5rinJMFwOfxT25BTX-KE1ICv9PcAmrDEeq4X4DTi2fh8RibdN8Jw7CSONQ6BhWuPF7GopC_gfIEuTo6_Tk5J6qpALGxWVkQrrymwzhe6kgb8i8YoURplclU4K6gWHiyYoZWCK-Ng_-Sp9oo1uigdY5S_RIO2a_0-wkCnKbOVZtqJvOEGvKmyFKWtqLW-oRnK1zNb2wQ5HjpfXNcx9c1l3XOjBk7UkRu1zNCHzTs3PeDGvdRHgWEbygCWHW90t_M6TWsNUmqp5-BbUSdAp5nclU7nDDSONg1VGTpYs7tOK3hZb-UtQ-82j2HthYSKbn1319MoHkDvMvSql47NSLgIaHoCRljtyM3OUHeftIuriO8tcy6EYhn6uJaw7bD-PxWv7_-LN-gRi0JfkFwdoMHq9s6_BX9qZUZoOB5PZ9NRWjwjtDcpJ6MYnfgNI-UiUg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ZbxMxELZKKgQviJuFAkaCJ7Dqtb2HHxBqS6uUthHqgfpmfG0aqWxKk4L6p_iNjL27icLRtz4mO1lNPIdnPJ5vEHoNLs6VvioI9VYSYb0gmtuU-EJKb0rmfJwSsTfI-0fi03F2vIR-db0w4Vpl5xOjo3ZjG87IV1nGZEi_Rfrh7DsJU6NCdbUbodGoxY6__Akp2-T99keQ7xvGtjYPN_qknSpALATrU6Kl1xRY95kuSgP7a2WkyI00qcycFVQLDx7c0ELCJ-Mgf_BUe8kqneWOMcrhvTfQsuA5ZT20vL45-Lw_P9UJ-QMXbXcO5eXqRMTrX-EmREBTL0m5sAPGQQH_im7_vqT5R6U2boBbd9GdNnLFa42q3UNLvr6PbjazLC8foGFs5QW9hRfhWteQjDeUJGyUDv_QNtTwJ7hFhsAn-lsAaZhgPdQjCFLxwdr-AdkYfyEMx8nlWONwkHHq8Sg2sTQNow_R0bWs9yPUq8e1f4Iw0GnKbKGZdiKtuIHoLc9Fbgtqra9ogtJuZZVtIc7DpI1TFUvtvFSNNBRIQkVpqDJBb2e_OWsAPq6kXg8Cm1EGcO74xfh8qNplVWAVlnoOsRx1AnyoSV3udMrAw2lTUZmglU7cqvUYEzXX7wS9mj0GWw8FHF378UVDI3kA2UvQ40Y7ZpxwEdD7BHBYLOjNAquLT-rRScQTL1MuhGQJetdp2Jyt_y_F06v_xUt0q3-4t6t2twc7z9BtFg0gI6lcQb3p-YV_DrHc1LxoDQijr9dts78BcaVdAw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrUBcEG8CBYwEJ3BxHOfhA4elZdVuoUKUot6MX9muVLJVdwvqH-J3MnayWy0UJA49JplYoxnPeGzPfAPwHF2cq3xdUuatpMJ6QXVmU-pLKb2puPOxS8SH3WJrXwwP8oMV-DmvhYlJ-xHSMrrpeXbY66mIWVQhoSCAkle0Wj92dZdMuePPfuBWbfpmexP1-oLzwbvPG1u06yZALQbpM6ql1wxZ9rkuK4Pram2kKIw0qcydFUwLj57bsFLik3G4b_BMe8lrnReOc5bhuFdgFeP7VPRgtd8f7g3PT3PCviETXVUOy6oLGF5a-WKDgIui2j-TM3-7oY0L3-Am3OgiVtJvZXQLVnxzG662PSzP7sAolvDifMWBSKMb3IS3lDQskI581zbc3U9JhwhBDvW3AM4wJXqkxxickr3-pz26MflCOYkdy4km4QDjyJNxLF5pC0Xvwv6lyPse9JpJ4x8AQTrNuC01106kdWYwaisKUdiSWetrlkA6l6yyHbR56LBxpOIVe1apVhsKNaGiNlSVwMvFP8ctsMc_qd8GhS0oAyh3fDE5GalOrAqtwTKfYQzHnEDfaVJXOJ1y9Gza1EwmsDZXt-o8xVTxnMtwrCTSBJ4tPqONh4sb3fjJaUsjswCul8D9dnYsOMlEQO0TyGG5NG-WWF3-0owPI454lWZCSJ7Aq_kMO2fr76J4-H_kT-Hax82Ber-9u_MIrvNoDzlN5Rr0Zien_jGGdDPzpLMnAl8v24R_AS2AW9k
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multivalent+nanoparticle-based+vaccines+protect+hamsters+against+SARS-CoV-2+after+a+single+immunization&rft.jtitle=Communications+biology&rft.au=Chiba+Shiho&rft.au=Frey%2C+Steven+J&rft.au=Halfmann%2C+Peter+J&rft.au=Kuroda+Makoto&rft.date=2021-05-19&rft.pub=Nature+Publishing+Group&rft.eissn=2399-3642&rft.volume=4&rft.issue=1&rft_id=info:doi/10.1038%2Fs42003-021-02128-8
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2399-3642&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2399-3642&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2399-3642&client=summon